the aid library

LIST OPTIONS

Filter

4395

A living WHO guideline on drugs for covid-19
recommended

Rochweg, B.; et al. (2021) CC

BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379 Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE... more

Download (121)

View PDF (114)

Urogenital schistosomiasis among school children in northwestern Tanzania: Prevalence, intensity of infection, associated factors, and pattern of urinary tract morbidities

Nyanda, C.J. ; T.R. Leeyio, A. Fuss, et al. (2024) CC

Parasite Epidemiology and Control Volume 27, November 2024, e00380 The planning and implementation of intervention measures against schistosomiasis, particularly mass administration, require knowledge of the current status of the infection. This is important for monitoring the impact of the interve... more

Download (224)

View PDF (382)

Abdominal tuberculosis in Ecuador, a problem that is still not solved

Rojas, C. L., Polanco E. C., Vivar M. C. et al. (2020) CC

Journal of Clinical TB and other Mycobacterial Diseases uberculosis (TB) in the gastrointestinal tract or peritoneum is an uncommon condition in clinical practice. Its rarity, combined with its nonspecific presentations, makes this kind of extrapulmonary tuberculosis difficult to diagnose as it can... more

Download (413)

View PDF (593)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (518)

View PDF (334)

Nursing Skills and Procedures - Pocket Guide

Anne Griffin, Patricia A. Potter Elsevir (2015) CC

Mosby’s Pocket Guide to Nursing Skills and Procedures, eighth edition, is a practical, portable reference for students and practitioners in the clinical setting. Grouped alphabetically, 85 commonly performed skills are presented in a clear, step-by-step format that includes: ■ Purpose for pe... more

Download (270)

View PDF (262)

Human African trypanosomiasis. Seminar

Büscher P., Cecchi G., Jamonneau V. et al (2017) C2

The Lancet Volume 390, Issue 10110p2397-2409November 25, 2017. Human African trypanosomiasis (HAT), also called sleeping sickness, is a parasitic infection that almost invariably progresses to death, unless treatment is provided. HAT caused devastating epidemics during the 20th century. Thanks to ... more

Download (352)

View PDF (432)

Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region

World Health Organization WHO WHO Regional Office for the Eastern Mediterranean (2014) CC

This publication represents a key step forward in translating Control of the leishmaniases (WHO Technical Report Series, No. 949) into a more practical tool for health personnel directly involved in the case management of cutaneous leishmaniasis. With this manual, countries will have, for the first ... more

Download (1300)

View PDF (2861)

Manual for the care and management of patients in Ebola Care Units/ Community Care Centres - Interim emergency guidance, January 2015
recommended

World Health Organization (2015)

This manual provides guidance on best practices to be followed in Ebola Care Units (ECUs)/Community Care Centres (CCCs). It is intended for health aid workers (including junior nurses and community health-care workers) and others providing care for patients in ECUs/CCCs. While the focus is on the ca... more

Download (413)

View PDF (302)

Hospital-based birth defects surveillance: facilitator guide

World Health Organization ( WHO), Regional Oﬃce for South-East-Asia (2016) C_WHO

Birth defect has been an emerging major cause of child mortality in the region. Scarcity of the birth defects information hampers policy decisions and control measures at national level. In order to create evidence for action for birth defects prevention in the region, WHO-SEARO in collaboration wit... more

Download (153)

View PDF (164)

Guidelines for Management of Type 1 Diabetes

Indian Council of Medical Research (2022) CC2

The ICMR type 1 diabetes guidelines come at a time when the SARS-CoV-2 pandemic has disproportionately affected people with diabetes population, exposing them to a high risk for severe illness and mortality. Globally, diabetes was responsible for over fourmillion deaths in the year 2019. It was th... more

Download (295)

View PDF (441)

Climate change and communicable diseases: a manual for health workers

World Health Organization. Regional Office for Europe (2011) C_WHO

There is a broad consensus nowadays that the Earth is warming up as a result of greenhouse gas emissions caused by anthropogenic activities. It is also clear that current trends in the fields of energy, development and population growth will lead to continuous and ever more dramatic climate change. ... more

Download (232)

View PDF (326)

Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons

World Health Organization WHO (2021) C_WHO

Interim guidance, 26 October 2021 This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021. SAGE said moderately and severely immunocompromised persons should be offered an addition... more

Download (330)

View PDF (311)

Implementation Framework & Clinical Guidance for Viral Hepatitis Prevention & Treatment 2019

Ministry of Health, Zambia (2020) CC

The Zambia Population Based HIV impact assessment of 2016, reported the prevalence of viral hepatitis in Zambia as ranging between 5.6% among adults aged 15 to 59% in the general population, and 7.1% among HIV infected individuals. It is estimated that the majority of persons with chronic hepatitis ... more

External Link

The Sphere Handbook. Humanitarian Charter and Minimum Standards in Humanitarian Response. New Edition
recommended

Sphere (2018) C1

Humanitarian Charter and Minimum Standards in Humanitarian Response. The 2018 Sphere Handbook builds on the latest developments and learning in the humanitarian sector. Among the improvements of the new edition, readers will find a stronger focus on the role of local authorities and communities as ... more

Download (261)

View PDF (330)

WHO Guideline on self-care interventions for health and well-being

World Health Organization WHO (2021) C_WHO

Self-care interventions are among the most promising and exciting new approaches to improve health and well-being, both from a health systems perspective and for people who use these interventions. The World Health Organization (WHO) uses the following working definition of self-care: Self-care i... more

Download (330)

View PDF (287)

Managing family risk: A facilitator’s toolbox for empowering families to manage risks during COVID-19. Part 1

World Health Organization WHO; IFRC; UNICEF and GOARN (2021) C_WHO

People-centered approaches that help communities maintain protective behaviours and follow guidelines set out by public health and government agencies are more important than ever. The evidence is clear, communities play a role in preventing and controlling epidemics and they are best able to take a... more

External Link

Gender and One Health context analysis for HEAL

Eba, B.; Wieland B., Flintan F., et al. (2020) CC

The One Health approach can help achieve progress and promotes synergies on national and global priorities by generating synergies at the human-animal-environmental interface. While evidence is still scare, it is likely that the approach is highly cost-effective and improves effectiveness of core pu... more

External Link

History, epidemiology and diagnostics of dengue in the American and Brazilian contexts: a review

Souza Salles, T.; T. da Encarnação Sá-Guimarães, E. Seam Lima de Alvarenga et al. (2018) CC

Parasites & Vectors volume 11, Article number: 264 (2018) Dengue creates a staggering epidemiological and economic burden for endemic countries. Without a specific therapy and with a commercial vaccine that presents some problems relative to its full effectiveness, initiatives to improve vector... more

Download (445)

View PDF (657)

Preparedness for the deliberate use of biological agents A rational approach to the unthinkable

World Health Organization (2002) C_WHO

For biological agents, the publication covers 11 bacteria, fungi and viruses listed by states parties to the Biological Weapons Convention in declarations of past offensive research and development programmes, or considered of special concern for possible use in terrorism. All of these agents c... more

Download (242)

View PDF (281)

Global elimination of dog-mediated human rabies. Report

World Health Organization (WHO) (2016) C_WHO

Rabies remains an under-reported neglected zoonosis with a case-fatality rate of almost 100% in humans and animals. Dog-mediated human rabies causes tens of thousands of human deaths annually despite being 100% preventable. More than 95% of human cases are caused by the bite of a rabies-infected dog... more

A living WHO guideline on drugs for covid-19 recommended

Manual for the care and management of patients in Ebola Care Units/ Community Care Centres - Interim emergency guidance, January 2015 recommended

The Sphere Handbook. Humanitarian Charter and Minimum Standards in Humanitarian Response. New Edition recommended

A living WHO guideline on drugs for covid-19
recommended

Manual for the care and management of patients in Ebola Care Units/ Community Care Centres - Interim emergency guidance, January 2015
recommended

The Sphere Handbook. Humanitarian Charter and Minimum Standards in Humanitarian Response. New Edition
recommended